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o Reflow and the
uest to Achieve Optimal
erfusion During the Acute
hase of Myocardial Infarction*
ernard R. Chaitman, MD, FACC,
ichael J. Lim, MD, FACC
t. Louis, Missouri
mproved survival in the acute phase of myocardial infarc-
ion (MI) is directly related to the speed at which the
ccluded infarct-related epicardial artery can be recanalized
fter symptom onset, the degree of patency achieved, and
he quality of restoration of blood flow to the microcircu-
ation and myocardium at risk. Three decades ago, Kloner et
l. (1) reported important capillary damage associated with
nterstitial and myocardial cellular edema after 90 min of
oronary occlusion in an experimental canine model with
lectron microscopy. More prolonged periods of coronary
See page 305
cclusion resulted in severe inflammation and disruption of
he capillary network. Similar processes occur in the clinical
etting of acute MI. However, in addition to the microcir-
ulatory damage caused by the ischemia-reperfusion injury,
lacement of a stent into a previously thrombosed vessel
ay result in distal embolization, spasm, and release of
asoactive mediators. When the pathophysiologic response
s severe, the slow or no reflow phenomenon occurs, defined
s adequate restoration of epicardial flow but poor or no
istal tissue-level perfusion (2).
Several years ago, the Stent Primary Angioplasty in
yocardial Infarction Study (STENT-PAMI) trial tested
ercutaneous transluminal coronary angioplasty with and
ithout stent placement and observed a non-significant
igher mortality rate in the stent group, perhaps accounted
or by a trend toward lower rates of Thrombolysis In
yocardial Infarction (TIMI) flow grade 3 or myocardial
lush grade (MBG) in the stent group (3). This led to an
ntense effort to optimally restore coronary blood flow, not
nly at the epicardial level, but also at the microcirculatory
evel in patients who received stents on the premise that
melioration of the no-reflow phenomenon might improve
urvival (4–8). The Controlled Abciximab and Device
nvestigation to Lower Late Angioplasty Complications
CADILLAC) was a multicenter clinical trial of 2,082
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the St. Louis University School of Medicine, Division of Cardiology, St.souis, Missouri.atients with acute MI (primarily, ST-elevation myocardial
nfarction [STEMI]) that presented within 12 h of symp-
om onset; patients were randomized to primary balloon
ngioplasty  abciximab versus primary stenting (Mul-
ilink)  abciximab, typically started minutes before the
rocedure. Recurrent ischemia and subacute thrombotic
vents were significantly reduced with abciximab treatment,
lthough there were no differences in one-year mortality
ates (4.1% for abciximab vs. 4.4% for placebo) (5).
In this issue of the Journal, Costantini et al. (9) examine
subset of 1,301 patients in a retrospective review of the
ADILLAC coronary angiograms and report improved
ne-year survival in patients who achieved greater tissue-
evel perfusion after therapy. De Luca et al. (10) reported
imilar findings after percutaneous coronary intervention
PCI) for STEMI in patients with heart failure. In the
ostantini et al. (9) study, tissue-level perfusion was as-
essed angiographically at the time of cardiac catheterization
y MBG; most patients did not achieve optimal blush
rade. Most patients did not achieve optimal blush grade.
espite TIMI flow grade 3 restoration in 96.1% of patients,
lush grade was normal in only 17.4% of subjects; 33.9%
ad reduced flow, and 48.7% had no-reflow. The one-year
ortality rates were 1.4%, 4.1%, and 6.2%, respectively (p
.01). The worse the blush grade, the worse the left
entricular function at seven-month follow-up angiography.
bciximab was not associated with better tissue-level per-
usion, nor was there an association between tissue-level
erfusion and the use of coronary stents compared with
alloon angioplasty alone. In other words, coronary stent-
ng, which requires deployment of a bulky stent at high
nflation pressures into a vessel with an acute thrombotic
rocess during acute MI, was not associated with worse
issue-level perfusion, an important observation because
any acute MI patients receive stents during their PCI
rocedure to prevent subacute closure and restenosis.
The reader should be cautious before extrapolating the
ostantini results to all patients who present with STEMI.
he CADILLAC trial excluded patients with cardiogenic
hock, saphenous vein graft lesions, relatively small infarct
essels, and longer lesions as well as patients requiring
rgent coronary bypass surgery; 12% of patients did not
ave STEMI or left bundle-branch block, and 45% of
atients had inferior MI. Thus, CADILLAC did not test
bciximab in a higher risk MI group, which, along with
ther protocol differences, may explain the discordant neg-
tive results of the CADILLAC trial with other earlier
maller, positive abciximab studies that included higher risk
ubjects (4,6).
A key issue in evaluating the efficacy of glycoprotein
Ib/IIIa blockade in improving tissue-level perfusion after
ecanalization of the infarct-related artery is the timing of its
dministration (11). In the Costantini study, the longer it
ook to achieve recanalization (i.e., later average time from
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Editorial Comment July 21, 2004:313–5BG 0/1 was observed. Early treatment after symptom
nset before the patient presents to the catheterization
aboratory for PCI would allow more time for abciximab to
ork, thus potentially reducing thrombus burden, allow for
etter visualization of the culprit lesion (which may facilitate
tent selection or identification of the infarct-related vessel
n a difficult patient with multivessel disease), improve
icrocirculatory flow, and facilitate the PCI procedure. In
ADILLAC, facilitated PCI with early pretreatment was
ot used, and abciximab was given minutes before the PCI
rocedure was performed, similar to other smaller trials
6,8). Large ongoing acute STEMI trials such as the
acilitated Intervention With Enhanced Reperfusion Speed
o Stop Events (FINESSE) may provide more definitive
nswers regarding the relationship between improved cor-
nary flow reserve (tissue-level perfusion) resulting from
arly pretreatment with abciximab before PCI and whether
r not this has an impact on long-term outcome (12).
Epicardial blood flow as assessed by MBG, as used in
ADILLAC, is a semi-quantitative method to assess the
icrocirculation. Direct assessment of coronary flow reserve
CFR) using a Doppler guide-wire technique provides a
ore direct method to assess microvascular reserve. In a
ecent study of patients with anterior MI undergoing PCI,
CFR 2 rather than MBG predicted recovery of left
entricular function (13). Angiographic techniques are lim-
ted to the timing of the procedure and are not well suited
or serial observations. Thus, a drug might well improve
oronary vascular reserve in the acute MI setting, but the
mprovement may occur just after the angiographic proce-
ure was terminated; later improvement in the microcircu-
ation may not be captured. Non-invasive imaging, for
xample, serial myocardial contrast echocardiograms or
erhaps serial electrocardiograms (e.g., resolution of ST-
egment elevation) may be better suited to indirectly mea-
ure tissue-level perfusion than angiographic methods and
hould be considered in the planning of future trials to assess
he microcirculation (8,14–16).
It is difficult to test the efficacy of drug therapy to improve
low or no-reflow and then prove that the improved survival
ith treatment is directly related to the change in flow
atterns at the microcirculatory level. Associations in a
etrospective analysis, as shown in the Costantini et al. (9)
tudy, are not the same as prospective serial observations in
ndividual patients with a prespecified hypothesis. To truly
nswer the question of whether improved tissue-level per-
usion is the right target for the assessment of the efficacy of
lycoprotein IIb/IIIa blockade, serial changes in the micro-
irculation of individual patients would need to be mea-
ured, and improvement in tissue-level perfusion shown to
e directly related to long-term outcome after adjustment
or other variables known to affect outcome. For example,
ne could hypothesize that abciximab might improve sur-
ival by reducing early recurrent ischemic-thrombotic events
r reducing the inflammatory process and that the survival
enefit with the drug has little to do with tissue-levelerfusion. Tissue-level perfusion might simply be a marker
f the duration of the ischemia/injury process (ischemia-
eperfusion injury), and an inappropriate target for the
ssessment of the benefits of abciximab therapy.
The era of placebo-controlled trials in acute STEMI to
ssess glycoprotein IIb/IIIa receptor blockade on restoration
f microcirculatory flow has probably passed because many
linicians would think it is unethical to withhold therapy
imply to test whether or not glycoprotein IIb/IIIa receptor
lockers improve tissue-level perfusion, given the reduction
n recurrent ischemic-thrombotic events and improved sur-
ival in higher risk patients observed with therapy. The
ostantini et al. (9) and De Luca et al. (10) studies
emonstrate the importance of considering the quality of
icrocirculatory reperfusion to estimate one-year survival.
learly, more research into methods to more rapidly restore
icrocirculatory flow, prevent distal emboli, and reduce
schemia-reperfusion injury is needed. In the meantime, the
uest to improve tissue-level perfusion and reduce the
o-reflow phenomenon, a frustrating experience to the
nterventional cardiologist who has just performed a won-
erful recanalization result, might be better achieved by a
ontinued intense national effort to reduce the time from a
atient’s symptom onset to successful recanalization of the
nfarct-related vessel.
eprint requests and correspondence: Dr. Bernard R. Chait-
an, St. Louis University School of Medicine, 1034 S. Brentwood
oulevard, Suite 1550, St. Louis, Missouri 63117. E-mail:
haitman@slu.edu.
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